Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities. In Vitro Cergutuzumab amunaleukin comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent CEA-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding. The activation of NK cells by Cergutuzumab amunaleukin (CEA-IL2v; 0.001-1000 nM) translated into increased killing of the CEA-positive colon cancer cell line LS180 accompanied by increased release of Granzyme B, IFNγ and RANTES and upregulation of CD25 and CD69 on NK cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In tumor-free mice, a strong expansion of peripheral CD 8+ T and NK cells after treatment with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (CEA-IL2v; i.v.; once) is observed . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Liquid